The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA ...

Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201 ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover advantage in a market with a large obese population. This move positions ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

In March 2025, the company announced positive initial results from a phase 1/2 study evaluating its lead pipeline candidate, BEAM-302, in treating alpha-1 antitrypsin deficiency (AATD).

After hours: 14 March at 19:56:11 GMT-4 Loading Chart for BEAM ...

After hours: March 21 at 7:57:41 p.m. EDT Loading Chart for EDIT ...

After hours: March 21 at 6:20:36 PM EDT Loading Chart for DTIL ...